RECURRENT WHO GRADE 3 GLIOMA
Clinical trials for RECURRENT WHO GRADE 3 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WHO GRADE 3 GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT WHO GRADE 3 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for brain cancer patients with rare gene fusion
Disease control Recruiting nowThis study tests a drug called erdafitinib in 30 adults with a specific type of brain tumor (glioma) that has returned or is growing. The tumor must have a particular gene change (FGFR-TACC fusion) and lack another common mutation (IDH-wild type). The drug works by blocking a fau…
Matched conditions: RECURRENT WHO GRADE 3 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
Engineered immune cells take on recurrent brain tumors in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment for people whose high-grade glioma (a type of brain cancer) has returned after previous therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called GARP found on tumo…
Matched conditions: RECURRENT WHO GRADE 3 GLIOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for recurrent brain tumors? drug combo enters early human testing
Disease control Recruiting nowThis early-stage trial tests a new two-drug combination for people whose glioblastoma (a type of brain cancer) has come back. The drugs, triapine and temozolomide, work by damaging cancer cell DNA to stop tumor growth. The main goal is to find the safest dose and understand side …
Matched conditions: RECURRENT WHO GRADE 3 GLIOMA
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC